AU2022206421A1 - Methods and compositions for rapid delivery of anti-seizure therapeutics - Google Patents

Methods and compositions for rapid delivery of anti-seizure therapeutics Download PDF

Info

Publication number
AU2022206421A1
AU2022206421A1 AU2022206421A AU2022206421A AU2022206421A1 AU 2022206421 A1 AU2022206421 A1 AU 2022206421A1 AU 2022206421 A AU2022206421 A AU 2022206421A AU 2022206421 A AU2022206421 A AU 2022206421A AU 2022206421 A1 AU2022206421 A1 AU 2022206421A1
Authority
AU
Australia
Prior art keywords
seizure
diazepam
subject
composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022206421A
Other languages
English (en)
Inventor
Enrique J. CARRAZANA
Stuart MADDEN
Edward T. Maggio
Sunita MISRA
Adrian L. RABINOWICZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurelis Inc
Original Assignee
Neurelis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurelis Inc filed Critical Neurelis Inc
Publication of AU2022206421A1 publication Critical patent/AU2022206421A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
  • Rolling Contact Bearings (AREA)
AU2022206421A 2021-01-08 2022-01-07 Methods and compositions for rapid delivery of anti-seizure therapeutics Pending AU2022206421A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163135291P 2021-01-08 2021-01-08
US63/135,291 2021-01-08
US202163276761P 2021-11-08 2021-11-08
US202163276760P 2021-11-08 2021-11-08
US63/276,761 2021-11-08
US63/276,760 2021-11-08
US202163284033P 2021-11-30 2021-11-30
US63/284,033 2021-11-30
PCT/US2022/011538 WO2022150540A1 (en) 2021-01-08 2022-01-07 Methods and compositions for rapid delivery of anti-seizure therapeutics

Publications (1)

Publication Number Publication Date
AU2022206421A1 true AU2022206421A1 (en) 2023-07-13

Family

ID=82323232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022206421A Pending AU2022206421A1 (en) 2021-01-08 2022-01-07 Methods and compositions for rapid delivery of anti-seizure therapeutics

Country Status (6)

Country Link
US (2) US20220218598A1 (https=)
EP (1) EP4274618A4 (https=)
JP (1) JP2024502466A (https=)
KR (1) KR20230144019A (https=)
AU (1) AU2022206421A1 (https=)
WO (1) WO2022150540A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117580579A (zh) * 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CA2756690C (en) * 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2694076A4 (en) * 2011-04-01 2014-08-27 Cpex Pharmaceuticals Inc Nasal formulations of benzodiazepine
EP4085899A1 (en) * 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine

Also Published As

Publication number Publication date
WO2022150540A1 (en) 2022-07-14
WO2022150540A9 (en) 2022-10-13
US20240299290A1 (en) 2024-09-12
US20220218598A1 (en) 2022-07-14
JP2024502466A (ja) 2024-01-19
EP4274618A4 (en) 2025-04-23
EP4274618A1 (en) 2023-11-15
KR20230144019A (ko) 2023-10-13

Similar Documents

Publication Publication Date Title
AU2021202433B2 (en) Neuroactive steroids, compositions, and uses thereof
US11096929B2 (en) Methods of treating developmental disorders with gaboxadol
WALBURGA et al. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
EP1942880A1 (en) A combination of cannabinoids for the treatment of peripheral neurophatic pain
US20200323823A1 (en) Methods for the treatment of depression
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
JP2021519349A (ja) 幻覚とそれに関連する病態の治療のための方法および組成物
US20240299290A1 (en) Methods and compositions for rapid delivery of anti-seizure therapeutics
US12599611B2 (en) Methods and compositions for treating seizure disorders in pediatric patients
Zadikoff et al. Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial
US20060084659A1 (en) Augmentation of psychotherapy with cannabinoid reuptake inhibitors
WO2025106879A1 (en) Methods of treating psychiatric disorders or pain using (r)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-one or pharmaceutically acceptable salts thereof
KR20230137404A (ko) Cbd를 사용한 수면 무호흡증의 치료
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
WO2025240537A1 (en) Methods of treating psychiatric disorders or pain using (r)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-one or pharmaceutically acceptable salts thereof
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
RYAN STORK et al. Pharmacologic Management of the Patient With Traumatic Brain Injury
WO2003015804A1 (en) Treatment to improve central nervous system function
AU2002328654A1 (en) Treatment to improve central nervous system function